AAAAAA
Results:
1-19
|
Results: 19
Authors:
Simon, LS
Citation: Ls. Simon, Cox-2 inhibitors - Are they nonsteroidal anti-inflammatory drugs with a better safety profile?, GASTRO CLIN, 30(4), 2001, pp. 1011
Authors:
Simon, LS
Citation: Ls. Simon, COX-2 inhibition: An advance or only pharmaceutical "hype"?, ARTH RH ART, 45(3), 2001, pp. 209-215
Authors:
Brandt, KD
Smith, GN
Simon, LS
Citation: Kd. Brandt et al., Efficacy of intraarticular hyaluronan in the treatment of knee osteoarthritis: comment on the article by Brandt et al - Reply, ARTH RHEUM, 44(6), 2001, pp. 1473-1476
Authors:
Simon, LS
Yocum, D
Citation: Ls. Simon et D. Yocum, New and future drug therapies for rheumatoid arthritis, RHEUMATOLOG, 39, 2000, pp. 36-42
Authors:
Simon, LS
Citation: Ls. Simon, DMARDS in the treatment of rheumatoid arthritis: Current agents and futuredevelopments, INT J CL PR, 54(4), 2000, pp. 243-249
Authors:
Simon, LS
Citation: Ls. Simon, Are the biologic and clinical effects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs?, CURR OP RH, 12(3), 2000, pp. 163-170
Authors:
Silverstein, FE
Faich, G
Goldstein, JL
Simon, LS
Pincus, T
Whelton, A
Makuch, R
Eisen, G
Agarwal, NM
Stenson, WF
Burr, AM
Zhao, WW
Kent, JD
Lefkowith, JB
Verburg, KM
Geis, GS
Citation: Fe. Silverstein et al., Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatorydrugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial, J AM MED A, 284(10), 2000, pp. 1247-1255
Authors:
Simon, LS
Citation: Ls. Simon, Cyclooxygenase 2 selective agents and upper gastrointestinal disease - Reply, J AM MED A, 283(15), 2000, pp. 1962-1962
Authors:
Brandt, KD
Smith, GN
Simon, LS
Citation: Kd. Brandt et al., Intraarticular injection of hyaluronan as treatment for knee osteoarthritis - What is the evidence?, ARTH RHEUM, 43(6), 2000, pp. 1192-1203
Authors:
Crofford, LJ
Lipsky, PE
Brooks, P
Abramson, SB
Simon, LS
Van de Putte, LBA
Citation: Lj. Crofford et al., Basic biology and clinical application of specific cyclooxygenase-2 inhibitors, ARTH RHEUM, 43(1), 2000, pp. 4-13
Authors:
Lipsky, PE
Brooks, P
Crofford, LJ
DuBois, R
Graham, D
Simon, LS
van de Putte, LBA
Abramson, SB
Citation: Pe. Lipsky et al., Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease, ARCH IN MED, 160(7), 2000, pp. 913-920
Authors:
Simon, LS
Citation: Ls. Simon, Viscosupplementation therapy with intraarticular hyaluronic acid - Fact orfantasy?, RHEUM DIS C, 25(2), 1999, pp. 345
Authors:
Simon, LS
Citation: Ls. Simon, Risk factors and current NSAID use, J RHEUMATOL, 26(7), 1999, pp. 1429-1431
Authors:
Simon, LS
Citation: Ls. Simon, The evolution of arthritis antiinflammatory care: Where are we today?, J RHEUMATOL, 26, 1999, pp. 11-17
Authors:
Simon, LS
Citation: Ls. Simon, The American College of Rheumatology core curriculum - A problem based learning curriculum: Rationale and design, J RHEUMATOL, 26, 1999, pp. 31-32
Authors:
Simon, LS
Weaver, AL
Graham, DY
Kivitz, AJ
Lipsky, PE
Hubbard, RC
Isakson, PC
Verburg, KM
Yu, SS
Zhao, WW
Geis, GS
Citation: Ls. Simon et al., Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis - A randomized controlled trial, J AM MED A, 282(20), 1999, pp. 1921-1928
Authors:
Simon, LS
Citation: Ls. Simon, Arthritis: New agents herald more effective symptom management, GERIATRICS, 54(6), 1999, pp. 37-42
Authors:
Lipsky, LPE
Abramson, SB
Crofford, L
Dubois, RN
Simon, LS
van de Putte, LBA
Citation: Lpe. Lipsky et al., The classification of cyclooxygenase inhibitors, J RHEUMATOL, 25(12), 1998, pp. 2298-2303
Authors:
Simon, LS
Zhao, SZ
Arguelles, LM
Lefkowith, JB
Dedhiya, SD
Fort, JG
Johnson, KE
Citation: Ls. Simon et al., Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis, CLIN THER, 20(6), 1998, pp. 1218-1235
Risultati:
1-19
|